Gluconat De Calciu Hameln

Gluconat De Calciu Hameln is a calcium gluconate injection solution supplied in a sterile aqueous form for intravenous administration. The product contains calcium gluconate as the active ingredient; the specific concentration is not disclosed in the summary. It is marketed in the European Union and is available only by prescription. The formulation is intended to provide a readily bioavailable source of calcium ions for clinical use.

Gluconat De Calciu Hameln is indicated for several clinical situations where calcium supplementation is required.

- Treatment of hypocalcemia resulting from surgical, traumatic, or metabolic causes. - Support of calcium levels during parenteral nutrition. - Cardiac membrane stabilization in patients with hyperkalemia undergoing emergency therapy. - Management of calcium deficiency associated with vitamin D deficiency or renal disease. - Adjunct therapy for magnesium toxicity to counteract neuromuscular excitability.

Adverse reactions to calcium gluconate injection are generally infrequent, but they can be categorized by frequency and severity.

Common: - Local irritation or pain at the injection site. - Mild nausea or vomiting. - Transient flushing or warmth sensation. - Mild hypotension when administered rapidly.

Serious: - Severe hypercalcemia with cardiac arrhythmias. - Tissue necrosis if extravasation occurs. - Allergic reactions such as urticaria, bronchospasm, or anaphylaxis.

Before administering Gluconat De Calciu Hameln, clinicians should consider several precautionary measures to minimize risk.

- Verify serum calcium levels; avoid use in patients with documented hypercalcemia. - Use a controlled infusion rate to prevent rapid shifts in calcium concentration. - Monitor cardiac rhythm and blood pressure during and after infusion. - Assess for signs of extravasation; discontinue infusion if tissue damage is suspected. - Use with caution in patients with renal impairment or active kidney stones. - Pregnancy and lactation status should be evaluated, as safety data are limited.

Calcium gluconate may interact with other medications, influencing their efficacy or safety.

Avoid: - Loop diuretics (e.g., furosemide) that increase calcium excretion. - Bisphosphonates administered concurrently, which can reduce calcium absorption. - Calcium‑containing antacids or oral supplements that may cause hypercalcemia.

Use with caution: - Digoxin, as calcium levels can affect its therapeutic window. - Cardiac glycosides and other drugs that prolong the QT interval. - Magnesium sulfate, because calcium may counteract its effects.